PHK
ENTA icon

Point72 Hong Kong’s Enanta Pharmaceuticals ENTA Stock Holding History

Point72 Hong Kong’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,169
Closed -$113K – 578
2022
Q3 		$113K Buy
2,169
+604
+39% +$35.3K ﹤0.01% 1198
2022
Q2 		$74K Buy
1,565
+713
+84% +$38.7K ﹤0.01% 1269
2022
Q1 		$61K Sell
852
-677
-44% -$44.1K ﹤0.01% 1286
2021
Q4 		$114K Buy
+1,529
New +$120K ﹤0.01% 1152
2021
Q2 		– Sell
-471
Closed -$23K – 2030
2021
Q1 		$23K Buy
+471
New +$23.5K ﹤0.01% 1445
2020
Q4 		– Sell
-853
Closed -$39K – 1807
2020
Q3 		$39K Sell
853
-80
-9% -$3.88K ﹤0.01% 734
2020
Q2 		$47K Buy
+933
New +$48.3K 0.01% 746
2019
Q3 		– Sell
-150
Closed -$13K – 1093
2019
Q2 		$13K Buy
150
+141
+1,567% +$12.7K ﹤0.01% 834
2019
Q1 		$1K Buy
+9
New +$807 ﹤0.01% 936
2018
Q4 		– Sell
-20
Closed -$2K – 971
2018
Q3 		$2K Buy
+20
New +$2K ﹤0.01% 771

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Point72 Hong Kong's ENTA Position: Q4 2022 in Review

Point72 Hong Kong sold out of Enanta Pharmaceuticals (ENTA) in Q4 2022, closing a stake of 2,169 shares — an estimated $113K sold.

Point72 Hong Kong first reported a position in ENTA in Q3 2018 and held it in 10 quarters. The position peaked at $114K in Q4 2021. 146 funds tracked by Wall St. Rank hold ENTA as of Q4 2022.

  • Point72 Hong Kong reported no remaining Enanta Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 2,169 Enanta Pharmaceuticals shares in Q4 2022, an estimated $113K.
  • Point72 Hong Kong first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 10 quarters.
  • Point72 Hong Kong's Enanta Pharmaceuticals position peaked at $114K in Q4 2021.
  • 146 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.